4 completed, 4 terminated, 3 recruiting, 1 active not recruiting. 7 Phase 1, 6 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 2, Terminated 2, Active not recruiting 1, Recruiting 1, Suspended 1 |
| Phase 2 | 6 | Completed 2, Recruiting 2, Terminated 2 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Refractory Ovarian Carcinoma: new trials by email Literature Review of Refractory Ovarian Carcinoma trials Research Report on Refractory Ovarian Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer CBX-12 - Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma | Phase 2 | Terminated | Cybrexa Therapeutics | 40 | 2024-09-25 | 2026-08-20 |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Suspended | National Cancer Institute (NCI) | 66 | 2022-02-02 | 2026-08-17 |
| Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Irinotecan Sucrosofate - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | Northwestern University | 3 | 2021-03-16 | 2023-01-19 |
| ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration - Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | Recruiting | Ira Winer | 62 | 2020-01-21 | 2026-06-17 |
| AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Batiraxcept, Durvalumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2019-12-03 | 2025-06-11 |
| Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients Cisplatin, Cytoreductive Surgery, Doxorubicin - Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm | Early Phase 1 | Terminated | Mayo Clinic | 2 | 2019-11-08 | 2025-02-20 |
| A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors TRPV6 Calcium Channel Inhibitor SOR-C13 - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 11 | 2019-07-29 | 2023-11-18 |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer PRGN-3005 UltraCAR-T cells - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Active not recruiting | Precigen, Inc | 71 | 2019-04-30 | 2024-11-08 |
| Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 4 | 2019-03-08 | 2024-09-19 |
| TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors Mivavotinib, Paclitaxel, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Ovarian Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 52 | 2019-03-05 | 2023-02-28 |
| Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Durvalumab, Tremelimumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 100 | 2017-05-18 | 2026-08-05 |
Ovarian Neoplasms (13) · Fallopian Tube Neoplasms (8) · Pancreatic Neoplasms (2) · Adenocarcinoma of Lung (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Desmoplastic Small Round Cell Tumor (1) · Liposarcoma (1) · Lung Neoplasms (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Pelvic Neoplasms (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1)
Adnexal Diseases (13) · Endocrine Gland Neoplasms (13) · Endocrine System Diseases (13) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Genital Diseases (13) · Genital Diseases, Female (13) · Genital Neoplasms, Female (13) · Gonadal Disorders (13) · Neoplasms (13) · Neoplasms by Site (13) · Ovarian Diseases (13) · Urogenital Diseases (13) · Urogenital Neoplasms (13) · Fallopian Tube Diseases (8)
Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · Disulfides (3) · Immunoglobulin G (3) · Paclitaxel (2) · Taxes (2) · X-Rays (2) · durvalumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · AVB-500 fusion protein (1) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Biopsy (1) · CTLA-4 Antigen (1) · Cell- and Tissue-Based Therapy (1)
M.D. Anderson Cancer Center (4) · Mayo Clinic (2) · Northwestern University (2) · Cybrexa Therapeutics (1) · Ira Winer (1) · National Cancer Institute (NCI) (1) · Precigen, Inc (1) · Roswell Park Cancer Institute (1)
United States (13)
Amir A Jazaeri (2) · Siqing Fu (2) · Amy R. Lankford, PhD (1) · Brenda J. Ernst, M.D. (1) · Daniela E Matei, M.D. (1) · Devalingam Mahalingam (1) · Emese Zsiros, MD (1) · Haider S Mahdi (1) · Ira Winer, M.D. (1) · Michael Needle, MD (1) · Patricio C. Gargollo, M.D. (1)
P30CA060553 (2), P30CA016672 (1), UM1CA186690 (1)